Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 7, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain operational or financial performance data for the period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction prices and volumes related to employee trusts and director holdings.
Material Changes
The filing details several share transactions occurring on January 2, 3, and 6, 2003, involving employee trusts and specific directors:
- Share Sales: The GSK Trust sold 11,345 Ordinary Shares on January 2, 2003, at a price of £11.715 per share.
- Share Purchases (Trusts): On January 3, 2003, the SmithKline Beecham Employee Benefit Trust purchased 1,363 shares for the Bonus Investment Plan and 2,296 shares for the Annual Investment Plan, both at £11.98 per share.
- Share Transfers: On January 3, 2003, 6,901 Ordinary Shares were transferred from the Trust to participants of the SmithKline Beecham 1991 Share Option Plan.
- Director Purchases: Directors Mr. J.D. Coombe, Mrs. G.A. Coombe, and Sir Peter Job purchased shares via a Single Company ISA on January 3, 2003, at £11.96 per share.
- Dividend Reinvestment: Mr. J.D. Coombe increased his holdings by 107 shares on January 6, 2003, via dividend reinvestment at £11.98 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, risk factors, contingencies, or unusual items. The document focuses exclusively on compliance reporting regarding director share interests.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust and SmithKline Beecham Employee Benefit Trust following the reported transactions.
- Confirm the aggregate shareholding of Directors Dr. J-P Garnier and Mr. J.D. Coombe, noting their indirect interests through the discretionary trusts.
- Review the company's broader 20-F annual report for comprehensive financial performance data, as this 6-K filing contains no financial statements.